📰 Mid Cap News
Page 64 - Mid Cap News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Mid Cap. Real-time updates on events, politics, business and more.
December 1, 2022
Regulatory News: Pershing Square Holdings, Ltd. (LN:PSH) (LN:PSHD) (NA:PSH) today released the following regular monthly Net Asset Value (NAV) and Performance Report for the month of November 2022.
November 27, 2022
Aristotle Capital Boston, LLC, an investment advisor, released its “Small/Mid Cap Equity” third quarter 2022 investor letter. A copy of the same can be downloaded here.
November 27, 2022
Aristotle Capital Boston, LLC, an investment advisor, released its “Small/Mid Cap Equity” third quarter 2022 investor letter. A copy of the same can be downloaded here.
November 27, 2022
Aristotle Capital Boston, LLC, an investment advisor, released its “Small/Mid Cap Equity” third quarter 2022 investor letter. A copy of the same can be downloaded here.
November 27, 2022
Aristotle Capital Boston, LLC, an investment advisor, released its “Small/Mid Cap Equity” third quarter 2022 investor letter. A copy of the same can be downloaded here.
November 25, 2022
STOCKHOLM, Nov. 25, 2022 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological
November 25, 2022
/PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat...
November 25, 2022
/PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat...
November 25, 2022
/PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat...
November 25, 2022
/PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat...